Shareholder Alert: Ademi LLP Investigates Whether Akili, Inc. Has Obtained a Fair Price for Its Public Shareholders
Shareholder Alert: Ademi LLP Investigates Whether Akili, Inc. Has Obtained a Fair Price for Its Public Shareholders
MILWAUKEE, May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutics.
密尔沃基,2024年5月29日 /PRNewswire/ — Ademi LLP正在调查Akili(纳斯达克股票代码:AKLI)在与Virtual Therapeutics的交易中可能违反信托义务和其他违法行为。
Click here to learn how to join the or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
点击此处了解如何加入或拨打 Guri Ademi 的免费电话 866-264-3995。您无需支付任何费用或承担任何义务。
In the transaction, Akili shareholders will receive only $0.4340 per share of common stock in cash. The transaction agreement unreasonably limits competing transactions for Akili by imposing a significant penalty if Akili accepts a competing bid. Akili insiders will receive substantial benefits as part of change of control arrangements.
在这笔交易中,Akili股东将仅获得每股普通股0.4340美元的现金。该交易协议不合理地限制了Akili的竞争交易,如果Akili接受竞争性出价,将处以巨额罚款。作为控制权变更安排的一部分,Akili内部人士将获得可观的收益。
We are investigating the conduct of Akili's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
我们正在调查Akili董事会的行为,以及他们是否履行了对所有股东的信托责任。
If you own Akili common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or
如果你拥有Akili普通股并希望获得更多信息,请致电 [email protected] 或免费电话:866-264-3995 与 Guri Ademi 联系,或
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
我们专门处理涉及收购、合并和全国各地个人股东权利的股东诉讼。欲了解更多信息,请随时致电我们。律师广告。先前的结果并不能保证类似的结果。
Contacts
联系人
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
Ademi LLP
Guri Ademi
免费电话:(866) 264-3995
传真:(414) 482-8001
SOURCE Ademi LLP
来源 Ademi LLP